Immuneering/$IMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Ticker
$IMRX
Sector
Primary listing
Employees
54
Headquarters
Website
Immuneering Metrics
BasicAdvanced
$388M
-
-$1.88
0.37
-
Price and volume
Market cap
$388M
Beta
0.37
52-week high
$10.08
52-week low
$1.10
Average daily volume
2.7M
Financial strength
Current ratio
3.703
Quick ratio
3.52
Long term debt to equity
12.557
Total debt to equity
13.826
Profitability
EBITDA (TTM)
-63.7
Management effectiveness
Return on assets (TTM)
-68.37%
Return on equity (TTM)
-130.47%
Valuation
Price to book
7.62
Price to tangible book (TTM)
10.07
Price to free cash flow (TTM)
-3.938
Free cash flow yield (TTM)
-25.39%
Free cash flow per share (TTM)
-1.557
Growth
Earnings per share change (TTM)
-1.60%
3-year earnings per share growth (CAGR)
1.43%
What the Analysts think about Immuneering
Analyst ratings (Buy, Hold, Sell) for Immuneering stock.
Bulls say / Bears say
IMM-1-104 in Phase 2a pancreatic cancer trial delivered an exceptional 94% overall survival rate at 6 months, far exceeding the approximately 67% benchmark for standard chemotherapy. (GuruFocus)
The clinical supply agreement with Eli Lilly to test atebimetinib combined with olomorasib in KRAS G12C-mutant NSCLC offers strong third-party validation and potential for dual targeting of the RAS–MAPK pathway. (Nasdaq)
Raised $25 million in a private placement at a 15% premium, demonstrating investor confidence and providing funding for ongoing clinical programs. (Investing.com)
Reported a net loss of $15.0 million in Q1 2025, highlighting continued high R&D expenses with no revenue to offset costs. (GuruFocus)
Private placement issuing 6.3 million new shares and warrants for an additional 2.8 million shares will dilute existing equity, potentially pressuring the stock. (Investing.com)
Cash balance of $26.4 million as of Q2 2025 provides runway into 2026 but remains tight ahead of pivotal Phase 3 studies, necessitating further funding rounds. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2025.
Immuneering Financial Performance
Revenues and expenses
Immuneering Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immuneering stock?
Immuneering (IMRX) has a market cap of $388M as of October 12, 2025.
What is the P/E ratio for Immuneering stock?
The price to earnings (P/E) ratio for Immuneering (IMRX) stock is 0 as of October 12, 2025.
Does Immuneering stock pay dividends?
No, Immuneering (IMRX) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Immuneering dividend payment date?
Immuneering (IMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immuneering?
Immuneering (IMRX) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.